Sign in

CIK 0001873835

  • Emerging growth company

Immix Biopharma, Inc.

Sign in to watch
Ticker
IMMX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
454869378
Phone
+1 888-958-1084
Business address
11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES, CA, 90064
Former names
Immix Biopharma, Inc.
  1. 4 Open-market buy CEO and Chairman bought 3,300 shares at $1.81 ($5,970)
  2. 4 Grant or award Director acquired 161,981 shares (grant or award)
  3. 4 Grant or award CEO and Chairman acquired 218,359 shares (grant or award)
  4. 4 Derivatives Options or other derivatives
  5. 4 Grant or award Director acquired 2,459 shares (grant or award)
  6. 4 Grant or award Director acquired 46,157 shares (grant or award)
  7. 4 Derivatives Options or other derivatives
  8. 4 Grant or award CFO acquired 242,500 shares (grant or award)
  9. 4 Open-market buy CFO bought 4,500 shares at $2.23 ($10,042)
  10. 4 Open-market buy CEO and Chairman bought 4,300 shares at $2.25 ($9,660)
  11. 4 Open-market buy Director bought 56,000 shares at an average $4.77 ($266,919)
  12. 4/A Derivatives Options or other derivatives
  13. 4/A Derivatives Options or other derivatives
  14. 4 Open-market buy Director bought 72,000 shares at an average $2.78 ($200,312)
  15. 4 Open-market buy Director bought 10,000 shares at $2.58 ($25,760)
  16. 4 Open-market buy Director bought 13,000 shares at $2.96 ($38,492)
  17. 4 Open-market buy Director bought 10,000 shares at $2.53 ($25,317)
  18. 4 Open-market buy Director bought 20,000 shares at $2.46 ($49,226)
  19. 4 Open-market buy Director bought 9,000 shares at $2.47 ($22,213)
  20. 4 Open-market buy Director bought 10,000 shares at $2.47 ($24,722)

Page 3 of 5 · 96 filings